8-K: Iridex Reports Mixed Q3 Results, Eyes EBITDA Breakeven in Q4

Iridex Corporation reported a revenue decline in Q3 2024 but anticipates achieving EBITDA breakeven in Q4 due to cost-cutting measures and improved profitability.

Summary

• Iridex Corporation announced its financial results for the third quarter of 2024, which ended on September 28, 2024.
• The company's total revenue for the quarter was $11.6 million, which is a decrease of 8% compared to the second quarter of 2024 and a 10% decrease compared to the third quarter of 2023.
• Revenue from the Cyclo G6 product family was $3.1 million, showing a 3% increase compared to the same quarter last year, with 13,600 probes sold compared to 13,200 in the prior year period.
• Retina product revenue was $6.5 million, a 12% sequential decline from the second quarter of 2024 and an 18% decline from the prior year period.
• The company strengthened its balance sheet with $3.4 million in net proceeds from a convertible note offering in August 2024.
• Iridex's cash and cash equivalents were approximately $3.9 million as of September 28, 2024.
• The company expects to achieve EBITDA breakeven in the fourth quarter of 2024 due to cost reductions and improved profitability.
• Gross profit for the quarter was $4.3 million, with a gross margin of 37.3%, down from $5.6 million and 43.7% in the same period last year.
• Operating expenses decreased to $6.2 million from $7.3 million in the same period last year due to cost reduction initiatives.
• The net loss for the quarter was $1.9 million, or $0.12 per share, compared to a net loss of $1.8 million, or $0.11 per share, in the same period last year.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the revenue decline and net loss, although the company is taking steps to improve profitability and is exploring strategic options. The positive outlook for glaucoma products is offset by the challenges in the retina business.

Positives

• The Cyclo G6 product family showed a 3% revenue increase year-over-year, indicating strength in the glaucoma segment.
• The company secured $3.4 million in funding through a convertible note offering, strengthening its balance sheet.
• New Medicare reimbursement policies are expected to positively impact the adoption of Iridex's glaucoma products.
• Iridex is actively pursuing strategic transactions, which could unlock value for shareholders.
• Cost reduction initiatives have led to a decrease in operating expenses.
• The company expects to achieve EBITDA breakeven in the fourth quarter of 2024.

Negatives

• Total revenue declined by 8% sequentially and 10% year-over-year, indicating a slowdown in sales.
• Retina product revenue experienced a significant decline of 12% sequentially and 18% year-over-year.
• Gross profit margin decreased from 43.7% to 37.3% year-over-year, impacting profitability.
• The company reported a net loss of $1.9 million for the quarter.
• There were shipment delays for certain products due to regulatory hurdles in some territories.

Risks

• The company is facing ongoing capital purchasing constraints both domestically and internationally, impacting system sales.
• Regulatory hurdles in some territories have caused shipment delays.
• The company's retina business is experiencing extended sales cycles.
• The company's strategic review process may not result in a value-maximizing transaction.
• The company's financial performance is subject to market conditions and competitive pressures.

Future Outlook

Iridex expects to achieve EBITDA breakeven in the fourth quarter of 2024 due to cost-cutting measures and improved profitability. The company also anticipates resolving regulatory issues that caused shipment delays in Q3 and expects to begin shipments in Q4.

Management Comments

• Patrick Mercer stated that the company was disappointed to see a return to extended sales cycles in the retina business.
• Patrick Mercer noted that the glaucoma business experienced stable demand and generated growth over the prior year period.
• Scott Shuda reported that the company has made meaningful progress in its strategic review and is in discussions with multiple parties.
• Scott Shuda commented that the changing reimbursement landscape for glaucoma treatments is bringing favorable attention to Iridex.

Industry Context

The announcement highlights the impact of changing reimbursement policies on the medical device industry, particularly in the glaucoma treatment sector. The new LCDs for Medicare reimbursement are expected to favor Iridex's glaucoma products, potentially increasing their adoption. The company's strategic review also reflects a broader trend of consolidation and strategic partnerships in the medical device industry.

Comparison to Industry Standards

• Iridex's revenue decline of 10% year-over-year is concerning, as many medical device companies are experiencing growth in the post-pandemic environment. For example, companies like Alcon and Johnson & Johnson Vision have reported positive growth in their ophthalmology segments.
• The gross margin of 37.3% is lower than the industry average for medical device companies, which typically ranges from 50% to 70%. Companies like Intuitive Surgical and Stryker maintain higher gross margins due to their premium pricing and strong market positions.
• The company's focus on cost reduction and achieving EBITDA breakeven is a positive step, but it needs to demonstrate sustainable revenue growth to compete effectively with larger players in the market.
• The strategic review process is similar to actions taken by other companies in the sector facing challenges, such as restructuring or seeking strategic partnerships to improve their competitive position.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the revenue decline and net loss, but may be encouraged by the potential for strategic transactions and the company's cost-cutting efforts.
• Employees may be affected by the cost reduction initiatives.
• Customers may experience delays in product shipments due to regulatory hurdles.
• Suppliers may be impacted by the renegotiation of contracts.

Next Steps

• Iridex will continue its strategic review process.
• The company will focus on resolving regulatory issues to resume shipments.
• Iridex will implement cost-cutting measures to achieve EBITDA breakeven in Q4 2024.
• The company will engage with physicians to promote the use of its glaucoma technology in light of the new LCDs.

Key Dates

Keywords

Iridex, EBITDA, Glaucoma, Retina, Medical Devices, Laser Technology, Financial Results, Reimbursement, Strategic Review, Cost Reduction